繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 肝病 >> 丙肝 >> 研究进展 >> 丙肝病毒性肝硬化发展为肝细胞癌的高危因素

丙肝病毒性肝硬化发展为肝细胞癌的高危因素

2009-08-28 11:41:38  作者:新特药房  来源:中国新药网  浏览次数:38  文字大小:【】【】【
简介:  丙型肝炎病毒(HCV)感染所致肝硬化可发展为肝细胞癌。意大利Bruno等学者的一项前瞻性研究显示,感染基因1型HCV是肝硬化患者发生肝细胞癌的高危因素。 研究自1989年1月至1990年12月共纳入163例HCV感 ...
 丙型肝炎病毒(HCV)感染所致肝硬化可发展为肝细胞癌。意大利Bruno等学者的一项前瞻性研究显示,感染基因1型HCV是肝硬化患者发生肝细胞癌的高危因素。

 研究自1989年1月至1990年12月共纳入163例HCV感染所致的肝硬化患者,其中104例患者感染基因1b型HCV,52例感染2a/c型HCV。患者每6个月接受1次超声检查,以监测肝细胞癌的发生,应用Cox回归分析评价发生肝细胞癌的独立危险因素。

 结果显示,经过平均10.7年的随访后,44例基因1b型HCV感染者发生肝细胞癌,10例基因2a/c型HCV感染者发生肝细胞癌(P=0.0001)。多因素分析显示,1b型HCV感染是发生肝细胞癌的独立危险因素。发生肝细胞癌的其他可预测因素有食管静脉曲张、男性、年龄超过60岁等。

研究者认为,1b型HCV感染易引起肝细胞癌,此型肝硬化患者应接受严密监测以发现早期癌变。

Hepatology. 2007 Nov;46(5):1350-6.

Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study.

Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU.

Liver Unit, Department of Medicine, Azienda Ospedaliera Fatebenefratelli e Oftalmico, Milan, Italy.

Hepatocellular carcinoma (HCC) is the most frequent cause of death in patients with hepatitis C virus (HCV)-induced cirrhosis. Despite a number of studies in different populations worldwide suggesting an association between HCV genotype 1 and the risk of HCC, no consensus has emerged yet on this matter, which is still controversial. In an attempt to clarify this issue, a prospective study of 163 consecutive HCV-positive patients with cirrhosis, who were enrolled between January 1989 and December 1990, was carried out. HCC occurrence was detected by ultrasound surveillance every 6 months. Independent predictors of HCC were assessed with a Cox regression analysis. After a median follow-up of 10.7 years, 44 [4.26/100/year, confidence interval (CI) = 3.11-5.68/100/year] of 104 patients infected with genotype 1b developed HCC versus 10 (1.69/100/year, CI = 0.82-3.09/100/year) of 52 patients infected with genotype 2a/c (P = 0.0001). Multivariate analysis showed that HCV genotype 1b was independently associated with HCC development [hazard ratio (HR) = 3.02, 95% CI = 1.40-6.53]. Other predictors of HCC were esophageal varices (HR = 2.15, 95% CI = 1.03-4.47), male gender (HR = 2.12, 95% CI = 1.10-4.11), and age over 60 years (HR = 5.96, 95% CI = 1.23-28.8). Conclusion: HCV genotype 1b is associated with a statistically significant higher risk of developing HCC. Patients with cirrhosis that are infected with this genotype require more intensive surveillance for the early detection and aggressive management of neoplasia.

责任编辑:admin


相关文章
甲苯磺酸索拉非尼片|NEXAVAR(sorafenib tablets)
Miripla(miriplatin)混悬液-用于肝细胞癌(HCC)的治疗
索拉非尼片|Nexavar(Sorafenib Tablets)
索拉非尼作为辅助治疗预防肝细胞癌复发的临床研究
HBVDNA水平与肝细胞癌发病率相关
肝细胞癌的分子靶向治疗
从循证医学角度看-索拉非尼治疗肝细胞癌的临床获益
预防耐药发生,实现更高治疗目标
Miripla(miriplatin,ミリプラ)-治疗肝细胞癌
索拉非尼(多吉美)治疗肝细胞癌的临床获益
 

最新文章

更多

· 丙型肝炎新药伯赛匹韦胶囊
· 慢性丙型肝炎抗病毒治疗...
· 慢性丙型肝炎复发和无应...
· telaprevir(prmise)-丙肝...
· 中西医治疗慢性丙型肝炎...
· 慢性丙型肝炎复发和无应...
· 派罗欣治疗慢性乙肝18例...
· 丙型肝炎患者接受肝移植...
· 基因药物干扰素α1b与α...
· 甘利欣与阿拓莫兰注射液...

推荐文章

更多

· 丙型肝炎新药伯赛匹韦胶囊
· 慢性丙型肝炎抗病毒治疗...
· 慢性丙型肝炎复发和无应...
· telaprevir(prmise)-丙肝...
· 中西医治疗慢性丙型肝炎...
· 慢性丙型肝炎复发和无应...
· 派罗欣治疗慢性乙肝18例...
· 丙型肝炎患者接受肝移植...
· 基因药物干扰素α1b与α...
· 甘利欣与阿拓莫兰注射液...

热点文章

更多